AI Pediatric Study Plan Development Playbook

A pharmaceutical company is developing an oncology drug that has received Breakthrough Therapy Designation. FDA has requested a Pediatric Study Plan (PSP) under PREA. The adult Phase 3 trial is enrolling. The clinical team is uncertain whether full pediatric trials are required or whether a waiver or deferral is appropriate.

When to use this playbook

• Use this playbook when the decision looks like the situation above: A pharmaceutical company is developing an oncology drug that has received Breakthrough Therapy Designation.
• It is a fit when you have source files in hand and need a structured, reviewable analysis — not a generic chat answer about "Pediatric Study Plan Development".
• Do not use it as a substitute for licensed, legal, clinical, or authorized official judgment in the domain.

What you'll need

• Adult Phase 3 trial protocol and current enrollment data
• FDA Breakthrough Therapy Designation letter
• FDA PREA requirements and pediatric oncology guidance
• Disease epidemiology in pediatric vs. adult populations
• Comparable oncology drug PSPs that received FDA agreement

Attachments: Documents (Documents)

You are a regulatory affairs specialist developing a Pediatric Study Plan for an oncology drug with Breakthrough Therapy Designation. I am attaching:

Work only from the attached source files. If a conclusion is not supported, say so.

Produce:
1. Assess whether the pediatric indication qualifies for a full waiver, partial waiver, or deferral — and what the scientific justification is for each determination.
2. If deferral is appropriate, design the pediatric study plan: which age groups, what study designs, what endpoints, and what timeline triggers.
3. Identify whether the Breakthrough Therapy Designation creates accelerated PSP review requirements or modified deferral standards.
4. Draft the waiver or deferral request language and the scientific justification FDA will require.
5. Tell me the PSP submission timing and what FDA is likely to push back on.

Call out where independent models are likely to disagree, and list follow-up documents a reviewer should request.

What to expect

• Waiver/deferral/full study determination with justification
• Pediatric study plan design by age group
• Breakthrough Therapy interaction with PSP requirements
• Waiver/deferral request language draft
• PSP submission timing and likely FDA pushback

Review before you act

• Validate this output against source files before relying on it: Assess whether the pediatric indication qualifies for a full waiver, partial waiver, or deferral — and what the scientific justification is for each determination.
• Validate this output against source files before relying on it: If deferral is appropriate, design the pediatric study plan: which age groups, what study designs, what endpoints, and what timeline triggers.
• Validate this output against source files before relying on it: Identify whether the Breakthrough Therapy Designation creates accelerated PSP review requirements or modified deferral standards.
• Validate this output against source files before relying on it: Draft the waiver or deferral request language and the scientific justification FDA will require.
• Confirm every cited figure, date, counterparty, or requirement against the attached originals — models compress and can drop a qualifier.
• Treat disagreement between models as a review item, especially on classification, materiality, and recommended next action.
• Do not authorize an operational, clinical, legal, credit, or enforcement action solely because the models agree.